Health ❯ Healthcare ❯ Patient Care

Treatment Options

Oral Medications Innovative Therapies Subcutaneous Administration Personalized Medicine Targeted Therapy Combination Therapy Chemotherapy Metastatic Cancer Endocrine Therapy Cognitive Impairment

FDA Approves Daraxonrasib for Advanced Pancreatic Cancer

The move could expand treatment options for people with RAS‑driven tumours.

Teva’s IL‑15 Antibody Meets Primary Goal in Mid‑Stage Celiac Trial

FDA Approves Rusfertide (Mimrylo) for Polycythemia Vera

FDA Approves First Broad RAS Inhibitor for Metastatic Pancreatic Cancer

FDA Approves Lisraya as First Oral Treatment for Adult Dermatomyositis

FDA Clears First Broadly RAS‑Targeting Pill for Advanced Pancreatic Cancer

FDA Approves Bixlenvo, a Once‑Daily Single‑Pill HIV Regimen

FDA Expands Approval of J&J’s Imaavy to Treat Warm Autoimmune Hemolytic Anemia

Upadacitinib Produces Major Hair Regrowth in Severe Alopecia in Phase 3 Trials

FDA Grants Accelerated Approval to Genglycos for Glycogen Storage Disease Type Ia

Amylyx’s Avexitide Cuts Moderate‑to‑Severe Post‑Bariatric Hypoglycemia Events 55% in Phase 3

Enhertu Improves Progression‑Free Survival in Phase 3 HER2‑Mutant Lung Cancer Trial

VA Shifts to Monitoring for Most Favorable‑Risk Prostate Cancers

FDA Grants Accelerated Approval for RP1 (Tudriqev) With Nivolumab in Advanced Melanoma

FDA Approves Lytenava, First Ophthalmic Bevacizumab for Wet AMD

EU Advisers Back Susvimo Implant as New Option for Wet Age‑Related Macular Degeneration

Anvisa Registers Columvi for Relapsed Diffuse Large B‑Cell Lymphoma

FDA Approves Lipfendra, First Oral PCSK9 Pill to Lower LDL Cholesterol

FDA Approves First Oral PCSK9 Pill, Merck’s Lipfendra

FDA Approves Revtorpyk for HER2‑Low Breast Cancer but Launch and Safety Questions Loom